Reaction profile

The FDA adverse-event record for bone marrow suppression

30 FDA reports name bone marrow suppression, a lower-volume reaction in the CVM extract (VeDDRA 150). Plate stamps and neighbourhood peers follow.

#1992 of 2,481
by report volume (all reactions)
30
reports citing this reaction
43.3%
death-coded share
Dog
most-affected species
Verify with FDA CVM →

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Bone marrow suppression has 30 reports now versus 28 in that prior snapshot: 2 more (7.1%).

Report change
+2
Death-coded reports
+0
Death-coded share
−3.1 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Bone marrow suppression changes

FDA AER · VeDDRA plate

Code 150 VOL-TRACE

VOL-TRACE · DEATH-HOT · LOWER-Q · PHOTO-FINISH · SPECIES-DOG · DRUG-LEAD · DESK-WIDE · BOOK-FULL

  • VOL-TRACE 30 reports
  • DEATH-HOT 43.3%
  • LOWER-Q #1992/2481
  • PHOTO-FINISH Abnormal spermatozoa…
  • SPECIES-DOG Dog · 20
  • DRUG-LEAD Oclacitinib Malea… · 5
  • DESK-WIDE 19 breeds
  • BOOK-FULL 8/8 fields

Nearest volume peer: Abnormal spermatozoa NOS (±0 reports)

Upper-third death-coded share drives the outcome stamps on this plate; volume band, corpus rank, and co-report peers follow. Not a clinical diagnosis.

Lower-volume neighbourhood around Bone marrow suppression

Lower-third volume poles plus nearest peers, not a full reaction corpus board reprint.

Vomiting · highest174348Abnormal spermatozoa… · near30Atelectasis · near30Bone marrow suppressi… · thi…30Chronic kidney disease · near30Congenital musculo-sk… · near30Urinary tract neoplas… · low…10
FDA AER report volume · neighbourhood around Bone marrow suppression

Bone marrow suppression: high death-coded share in the FDA AER plate

Signature read: Bone marrow suppression's 43.3% death-coded share is among the highest in the openFDA reaction corpus. Report volume is lower-third scale: 30 named reports in the openFDA extract. Death-coded share is upper-third: 13 of 30 reports (43.3% of named reports). Nearest volume peer: Abnormal spermatozoa NOS (±0 reports). Lead species Dog (20). Lead co-reported drug Oclacitinib Maleate (5).

Read these counts as reporting volume, not risk: per our methodology, A high death-coded share in FDA filings does not prove causation; co-reporting is voluntary temporal association only. Browse the full reactions index or the about page for how PlainBreed frames FDA CVM extracts.

Species Most Affected

Dog 20
Cat 8
Alpaca 1
Horse 1

Breeds Most Affected

Domestic Shorthair 7
Retriever - Labrador 4
Crossbred Canine/dog 2
Terrier - Bull 2
Dachshund (unspecified) 1
Kuvasz 1
Terrier - Scottish 1
Alpaca 1
Great Pyrenees 1
Alaskan Malamute 1

Associated Drugs

Oclacitinib Maleate 5
Cefovecin 3
Maropitant Citrate 3
Selamectin 3
Imidacloprid + Moxidectin 2
Moxidectin 2
Estriol Tablets 2
Doxycycline 2
Oclacitinib 2
Feline Leukemia Virus, Ah927/1161E Strain 2
Robenacoxib 2
Ilunocitinib 2
Ketoconazole 2
Gabapentin 2
Fluoxetine Hydrochloride 2
Cephalexin 2
Metronidazole 2
Blood Transfusion 2
Kaolin + Pectin + Enterococcus Faecium 2
Prebiotic 2

What to do with this reaction

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Bone marrow suppression (#1992 of 2,481 by report volume); death-coded 43.3%. PlainBreed reaction plate · death-coded share stamp 43.3% · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →